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It is widely accepted that the majority of cancers result from multiple cellular events leading to malignancy after a
prolonged period of clinical latency, and that the immune system plays a critical role in the control of cancer
progression. Bovine leukemia virus (BLV) is an oncogenic member of the Retroviridae family. Complete genomic
sequences of BLV strains isolated from peripheral blood mononuclear cells (PBMC) from cattle have been previously
reported. However, a detailed characterization of the complete genome of BLV strains directly isolated from bovine
tumors is much needed in order to contribute to the understanding of the mechanisms of leukemogenesis
induced by BLV in cattle. In this study, we performed a molecular characterization of BLV complete genomes from
bovine B-cell lymphosarcoma isolates. A nucleotide substitution was found in the glucocorticoid response element
(GRE) site of the 5' long terminal repeat (5'LTR) of the BLV isolates. All amino acid substitutions in Tax previously
found to be related to stimulate high transcriptional activity of 5'LTR were not found in these studies. Amino acid
substitutions were found in the nucleocapsid, gp51 and G4 proteins. Premature stop-codons in R3 were observed.
Few mutations or amino acid substitutions may be needed to allow BLV provirus to achieve silencing. Substitutions
that favor suppression of viral expression in malignant B cells might be a strategy to circumvent effective immune
attack.Introduction
Bovine leukemia virus (BLV) is a B-lymphotropic onco-
genic member of the Retroviridae family that infects cat-
tle worldwide and is the causative agent of enzootic
bovine leukosis (EBL), a neoplastic proliferation of B
cells [1,2]. BLV infection is characterized by a long
period of viral latency and by the absence of viremia.
This is thought to be related to the transcriptional re-
pression of viral expression in vivo [3]. Latency is likely
a viral strategy to evade the host immune response,
thereby allowing tumor development [4,5]. In fact, B
lymphocytes harboring an integrated provirus do not
produce detectable levels of viral RNA or proteins [6].
Nevertheless, when these cells are isolated and cultured
in vitro, a marked increase in viral transcription occurs,* Correspondence: cristina@cin.edu.uy
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reproduction in any medium, provided the orsuggesting that the provirus is maintained at a repressed
stage in vivo [7].
Regarding genome organization, as in all retroviruses,
BLV has the gag, pro, pol, env structural genes (from 5′
to 3′ of the genome) required for the production of in-
fectious virions [8]. In addition to these genes, the BLV
genome contains an X region located between the env
gene and the 3′ long terminal repeat (3′-LTR) [9], as
also observed in other Deltaretroviruses [10]. This re-
gion contains the open reading frames of four regulatory
proteins: the transactivator protein, Tax [11]; the Rex
protein, which stabilizes and allows exportation through
the cytoplasm of viral RNA [12] and two accessory pro-
teins R3 and G4 whose small open reading frames
(ORF) are located in the region between the env gene
and the tax/rex genes [13]. Deletion of R3 and G4 genes
of BLV in an infectious and tumorigenic BLV molecular
clone induced loss of the leukomogenic phenotype andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in vitro [14,15].
The BLV transcriptional promoter is located in the 5′
long terminal repeat (5′-LTR) and is composed of the
U3, R and U5 regions. Gene expression is induced at the
transcriptional level by the virus-encoded transactivator
Tax [16].
Few complete genomic sequences of BLV strains are
available in the databases. These sequences are from differ-
ent sources: peripheral blood mononuclear cells (PBMC)
[17], tumor cells, experimentally infected sheep, and cell
lines (FLK). The degree of genetic variation among these
strains and those directly isolated from bovine B-cell lym-
phosarcomas remains unknown. For this reason, and in
order to contribute to the understanding of the mecha-
nisms of leukemogenesis induced by BLV, we performed a
detailed characterization of the complete genome of three
BLV isolates from B-cell lymphosarcomas of three cows
from different farms, and we compared them with all avail-
able and corresponding full length sequences from BLV
isolates from other sources.
Materials and methods
Lymphosarcoma samples were obtained by certified vet-
erinary doctors following appropriate ethical guidelines
from national and international veterinary associations.
The project was also read and approved by Institut
Pasteur-Montevideo, Uruguay.
Animals
Lymphosarcoma samples were obtained from three dairy
cows proven to be infected with BLV by PCR and ELISA
(VMRD Inc., Pullman, WA, USA).
DNA extraction and PCR amplification
DNA samples were extracted from lymphosarcoma tis-
sue and FLK cells (as a control), using the QiAmp DNA
Blood Mini kit from QIAGEN, according to the instruc-
tions supplied by the manufacturer. PCR amplification
of overlapping genome fragments covering the complete
genome of BLV was achieved using Phusion DNA Poly-
merase (New England BioLabs) and specific primers
designed for this study (synthesized by Integrated DNA
Technologies, Leuven, Belgium and shown in Additional
file 1). The location of each amplicon is shown in
Additional file 2. Reagents for PCR were from New Eng-
land BioLabs. The final reaction mixture (50 μL)
contained 1x HF buffer, 200 μM dNTP, 200 nM of each
primer, and 1 U Taq polymerase. The cycle for the PCR
amplification were as follows: 98°C for 30 s, then 30 -
cycles of denaturation at 98°C for 10 s, annealing at
55–65°C for 30 s, and extension at 72°C for 1–3 min,
followed by a final extension at 72°C for 10 min. ThePCR reactions were carried out using an Eppendorf
Mastercycler Gradient PCR Thermal Cycler.
Amplicon purification and cloning
Amplicons were resolved by 1% agarose gel electrophor-
esis, stained with ethidium bromide and purified using
QIAquick PCR Purification Kit from QIAGEN, according
to instructions from the manufacturers, and cloned into
pGEM T- Easy vector (Promega). Electrocompetent
XL1-Blue bacteria were transformed by colonies and
were expanded and small-scale plasmid purification
was performed using the GFX DNA purification kit
(GE Healthcare, Piscataway, NJ, USA).
Sequencing
Both strands of purified plasmids were sequenced in order
to avoid discrepancies by using specific and universal T7 or
SP6 primers and the Big Dye DNA sequencing kit (Perkin-
Elmer) on a 373 DNA sequencer apparatus (Perkin-Elmer).
Complete genome sequences were obtained from B-cell
lymphosarcomas and deposited in the EMBL database
under accession numbers EMBL:HE967301 to EMBL:
HE967303 (LS1to LS3). Complete genome sequences were
obtained for all available and comparable BLV strains by
using All-round Retrieval of Sequence and Annotation
(ARSA) at the DNA Data Bank of Japan (DDBJ) [18].
Sequence alignment
Sequences were aligned using the CLUSTAL W pro-
gram [19].
Protein sequences
Protein sequences were obtained by means of in silico
translation of nucleotide to amino acid sequences. This
was done by using software from the MEGA program [20].
Results and discussion
Comparison of the 5′-LTR genome region of BLV strains
isolated from lymphosarcomas and other origins
BLV initiates transcription at the U3-R junction of the 5′-
LTR induced by Tax protein [16]. Transactivation requires
the presence of three 21-bp enhancer elements (called
Tax-responsive elements, TxRE) located in the U3 region
of the 5′-LTR [21]. Each TxRE contains an octanucleotide
core sequence corresponding to an imperfectly conserved
cyclic AMP-responsive element (CRE), which binds cellu-
lar transcription factors like CRE-binding protein (CREB),
CRE-modulator τ isoform (CREMτ), and activating tran-
scription factors 1 and 2 (ATF-1 and ATF-2) [22]. TxRE
also contains an E-box sequence, which overlaps each of
the three CRE motifs, and binds proteins that belong to
the basic helix-loop-helix (bHLH) family of transcription
factors, including c-Myc, Max, USF or TFE3 [23]. The U3
region also contains a PU.1/Spi-B binding site [24] and a
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BLV expression is regulated by 5′-LTR sequences down-
stream of the transcription initiation site: a 64-bp down-
stream activator sequence (DAS) at the 3′ end of the R
region [26] and an interferon regulatory factor binding site
in the U5 region [27]. A scheme showing the positions of
all these elements in BLV 5′-LTR is shown in Figure 1.
Comparison of the 5′-LTR genomic sequences of the
three BLV lymphosarcoma isolates (LSI) with all avail-
able complete BLV genome sequences, revealed that this
genome region is highly conserved (Figure 1). The only
significant difference between LSI and those isolated
from other cell types, e.g. PBMC or FLK cells, is a base
substitution found at position 150 (G to A) in the third
enhancer element of this region, at the GRE binding site
(Figure 1). It has been previously found that GRE con-
fers responsiveness to glucocorticoids such as dexa-
methasone in the presence of the Tax transactivator [28].
However, in the absence of Tax, mutation of the GRE
significantly decreases basal LTR activity as shown in
reporter-based assays [25]. This raises the possibility that
this substitution may have allowed a better silencing of
viral transcription in the lymphosarcoma strains, as a
strategy to avoid recognition by the host immune re-
sponse [25].
Comparison of deduced amino acid sequences from
structural proteins of BLV LSI with those of other origins
In order to detect differences among BLV LSI and isolates
from PBMC and other origins, the amino acid sequences
of structural proteins encoded by gag, pro, pol, and env
genes were aligned. Gag is a polyprotein precursor that is
cleaved in the mature virions giving rise to the following:
matrix (p15- MA), capsid (p24-CA) and nucleocapsid
(p12-NC) proteins (see Figure 2A). NC proteins among all
retroviruses share as a major characteristic the presence of
a high percentage of basic residues as well as zinc binding
domains involved in RNA packaging, both of which are
well conserved in all BLV isolates. Indeed, previous studies
have shown that substitutions in either basic amino acid
residues or zinc finger domains led to a significant reduc-
tion in viral RNA packaging [29]. In that sense, a proline
to serine (P340S) substitution was observed in the NC
protein of all BLV LSI (Figure 2A). This substitution could
potentially increase side chain hydrophylicity and be in-
volved in the elimination of the structural restriction re-
lated to proline presence. Interactions of NC with RNA
sequences, besides those RNA secondary structures of the
RNA packaging signal, has been demonstrated for other
retroviruses, e.g., murine leukemia virus (MLV) and spleen
necrosis virus (SNV). These interactions play an important
role in the RNA packaging of these viruses [30,31].
BLV protease (PR) is an aspartic protease with a func-
tional activity involved in gag processing and thus invirion maturation. Previous work proposed a molecular
model for BLV PR as well as its substrate specificity,
cleavage type sites and inhibitor sensitivity [32]. The
comparison of amino acid sequences of PR of BLV LSI
with all other sequenced BLV isolates examined in this
study is shown in Figure 2B. Only one amino acid sub-
stitution (V165I) was found among the BLV lymphosar-
coma isolates and is not related to sites previously
reported to be involved in BLV PR function via main-
chain atoms of peptide substrates or residues predicted
to form cleavage subsites [32,33]. Two substitutions can
be observed at positions 37–38 in lymphosarcoma BLV
isolate LS1, as compared to other genomic sequences in-
cluding LS2 and 3 isolates (see Figure 2B).
Two amino acid substitutions can be found in the
polymerase precursor of all three BLV isolates, one lo-
cated in the RT (T378A), the other in the endonuclease
region (S573P) (see Figure 3).
This substitution could involve important structural
changes, but unfortunately, the structure of BLV poly-
merase as well as other related Deltaretroviruses, like
HTLV-1, is currently unknown.
Further studies will be needed to establish if these sub-
stitutions can affect polymerase fidelity or processivity.
The Env protein complex is composed of two compo-
nent subunits: gp51 surface (SU, N- terminal portion)
and gp30 transmembrane (TM, C-terminal portion),
which remain associated as a functional trimer with
three SU subunits linked by disulphide bonds to a spike
of three TM subunits [34]. The gp51protein recognizes
and binds to cellular receptors, thereby initiating con-
formational changes that lead to fusion of viral and cel-
lular membranes by gp30 oligomers [35].
Previous studies have shown that the N-terminal por-
tion of mature gp51 plays an important role in virus in-
fectivity [36]. This region is composed of conformational
epitopes F, G and H [37] followed by the structural
strong turn GYDP, which is conserved in all oncogenic
retroviruses [38]. This motif separates the conform-
ational epitope region from the C-terminal domain of
gp51 that contains the linear epitopes A, B, D and E [39]
(see Figure 4). Comparison of Env protein of BLV LSI
with other previously described isolates, reveals an
amino acid substitution in SU conformational epitope
region (D134N) in a location previously shown to be re-
lated to neutralization [39] (Figure 4). However, this sub-
stitution has been previously described as a signature of
BLV strains circulating in Uruguay, and it is not specific
for LS samples [40].
Comparison of deduced amino acid sequences from non-
structural proteins of BLV LSI and other origins
Previous studies on the functional domains of the BLV
Tax protein have identified a putative zinc finger motif
1 50 CRE E Box CRE E Box 100
LS1   TGTATGAAAGATCATGCCGACCTAGGCGCCGCCACCGCCCCGTAAACCAGACAGAGACGTCAGCTGCCAGAAAAGCTGGTGACGGCAGCTGGTGGCTAG
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ...................................................................................................
FJ914764   ...................G....................T..............A...........................................
K02120     ..........................A........................................................................
AF257515 ...................G....................T..............A...........................................
CAT Box PU.1/Spi-B GRE 150 CRE  E Box PROMT    PAS 200
LS1   AATCCCCGTACCTCCCCAACTTCCCCTTTCCCGAAAAATCCACACCCTAAGCTGCTGACCTCACCTGCTGATAAATTAATAAAATGCCGGCCCTGTCGA
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ................................................G..................................................
FJ914764   ................................................G..................................................
K02120     ................................................G..................................................
AF257515 ................................................G..................................................
CAP SITE    U3| R 250 300
LS1   GTTAGCGGCACCAGAAGCGTTCTTCTCCTGAGACCCTCGTGCTCAGCTCTCGGTCCTGAGCTCTCTTGCTCCCGAGACCTTCTGGTCGGCTATCCGGCA
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ...................................................................................................
FJ914764   ..............................................................T.................................C..
K02120     ..................................................... ..............................................
AF257515 ..............................................................T.................................C..
350 DAS E Box 400
LS1   GCGGTCAGGTAAGGCAAACCACGGTTTGGAGGGTGGTTCTCGGCTGAGACCACCGCGAGCTCTATCTCCGGTCCTCTGACCGTCTCCACGTGGACTCTC
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ...................................................................................................
FJ914764   ............................................................................G......................
K02120     .................G.-...............................................................................
AF257515 ............................................................................G......................
450
R|   U5 IRF 500
LS1   TCCTTTGCCTCCTGACCCCGCGCTCCAAGGGCGTCTGGCTTGCACCCGCGTTTGTTTCCTGTCTTACTTTCTGTTTCTCGCGGCCCGCGCTCTCTCCTT
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ...................................................................................................
FJ914764   ..TC..................................................C............................G...........T...
K02120     ...................................................................................................
AF257515 ..TC..................................................C..................G.........G...........T...
550
U5|  tRNAPro Bind site 600
LS1   CGGCGCCCTCTAGCGGCCAGGAGAGACCGGCAAACAATTGGGGGCTCGTCCGGGATTGATCACCCCGGAACCCTAACAACTCTCTGGACCCACCCCCTC
LS2        ...................................................................................................
LS3        ...................................................................................................
EF600696   ............................................................................T......................
FJ914764   ...............................................................................T...................
K02120     ...................................................................................................
AF257515 ..........TC...................................................................T...................
LS1   GGCGGCATTTTGGGTCTCTCCTTCAAATTATATC
LS2 ..................................
LS3 ..................................
EF600696   ..................................
FJ914764   ......G..........T................
K02120     ..................................
AF257515 ......G..........T..............CT
Figure 1 Alignment of 50LTR nucleotide sequences of BLV strains. BLV strains isolated from PBMC cells and previously described are shown
by accession number on the left side of the figure. BLV isolates from B-lymphosarcoma tumors (LS1 through LS3) are shown by name. Identity
with BLV strain LS1 is indicated by a dot. The U3, R, and U5 regions are indicated on top of the alignment. The three TxRE enhancer regions are
shown in green, cyclic AMP- responsive element (CRE) sequences are underlined and E-Box sequences are shown in italics. Binding sites for
PU.1/Spi-B are shown in bold. The glucocorticoid responsive element (GRE) binding site is shown in bold, italics and underlined. Nuclear factor κB
(NF-κB) binding sites are shown double underlined. The CAT box and GATAA box promoters (PROMT) sequences are indicated in yellow and in
bold italics, respectively. The polyadenylation site (PAS) is shown in magenta and the CAP site is shown in light blue. The tRNA proline primer
binding sites are shown in red. The downstream activator sequence (DAS) and the interferon regulatory factor (IRF) binding sites are shown in
dark and light grey, respectively.
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(A) gag
1 P15-MA 50 100
LS1   MGNSPSYNPPAGISPSDWLNLLQSAQRLNPRPSPSDFTDLKNYIHWFHKTQKKPWTFTSGGPTSCPPGRFGRVPLVLATLNEVLSNDGGAPGASAPEEQP
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   .....................R........................................A.....K..................E............
FJ914764   ...............................................Y............S............................T..........
K02120     ......................................................................................E.............
AF257515   ...............................................Y............S............................T..........
101 P24-CA 150 200
LS1   PPYDPPAVLPIISEGNRNRHRAWALRELQDIKKEIENKAPGSQVWIQTLRLAILQADPTPADLEQLCQYIASPVDQTAHMTSLTAAIAAAEAANTLQGFN
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   .......I............................................................................................
FJ914764   ....................................................................................................
K02120     .......I....................................................................................-.......
AF257515   ...........................V........................................................................ 
201 250 300
LS1   PQNGTLTQQSAQPNAGDLRSQYQNLWLQAWKNLPTRPSVQPWSTIVQGPAESYVEFVNRLQISLADNLPDGVPKEPIIDSLSYANANKECQQILQGRGLV
LS2   ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   ....................................................................................................
FJ914764   ................................................S...................................................
K02120     .............................-......................S...................-..............R..........-.
AF257515   ....................................................................................................
301 P12-NC 350Zn finger Zn finger
LS1   AAPVGQKLQACAHWAPKMKQPAILVHTPGPKMPGPRQPASKRPPPGPCYRCLKEGHWARDCPTKATGPPPGPCPICKDPSHWKRDCPTLKSKN
LS2        .............................................................................................
LS3        .............................................................................................
EF600696   .................V....V................P.....................................................
AF033818   .................V.....................P........................T............................
FJ914764   .................I.....................P........................T.............L..............
K02120     .--...................L................P.....................................................
AF257525   .................I.....................P........................T.............L..............
(B) pro
1 50 100
LS1    RSFPLETRLSNPQIKKLIEGGLSAPQTITPITDSLSGTELECLLSIPLARSRPSVAVYLSGPWLQPSQNQALMLVDTGAENTVLPQNWLVRDYPRIPAAV
LS2     ....................................EA..............................................................
LS3         ....................................EA..............................................................
EF600696    ....................................EA..............................................................  
AF033818    ...........................V.....P..EA.............................................................. 
FJ914764    ...........................T........EA.............................R...........................T....   
K02120      ....................................EA..............................................................
AF257525    ...........................T........EA.....................................................E...T.... 
101 150
LS1   LGAGGVSRNRYNWLQGPLTLALKPEGPFITIPKILVDTFDKWQILGRDVLSRLQASISIPEEIRPPVVG
LS2        .....................................................................
LS3        .....................................................................
EF600696   ..............................................................V......
AF033818   ..............................................................V...M..
FJ914764   ..............................................................VP.....
K02120     .......................................S......................V......
AF257515   .....I.......S..L....I........................................V......
Figure 2 Alignment of amino acid sequences of Gag and Protease (Pro) proteins of BLV isolates. In (A), alignment of Gag polyprotein
sequences is shown. Matrix (p15-MA), capsid (p24-CA) and nucleocapsid (p12-NC) protein sequences are shown in green, light blue and magenta,
respectively. Zinc finger domains are shown in bold and italics. NC residues in boldface indicate basic residues. Conserved residues among BLV,
HTLV-1 and HTLV-2 are shown bold underlined. In (B) alignment of protease (Pro) sequences is shown. Residues proven or predicted to be
involved in S2 binding subsites are shown in bold. Residues that appear in HIV-1 drug resistance at the equivalent position in HIV-1 protease [32]
are shown in bold underlined. The rest is the same as Figure 1.
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1 Reverse transcriptase 50 100
LS1 GASIPFKLERLQALQDLVHRSLEAGYISPWDGPGNNPVFPVRKPNGAWRFVHDLRATNALTKPIPALSPGPPDLTAIPTHLPHIICLDLKDAFFQIPVED
LS2      ....................................................................................................




K02120   ................................................................................P...................
AF257515 .T............................................T.................R.PP................................
101 150 200
LS1   RFRSYFAFTLPTPGGLQPHRRFAWRVLPQGFINSPALFERALQEPLRQVSAAFSQSLLVSYMDDILIASPTEEQRSQCYQALAARLRDLGFQVASEKTRQ
LS2     ....................................................................................................




K02120   ...F.LS....S......................................................Y...............................S.
AF257515 ...................................................T................................................
201 250 300
LS1   TPSPVPFLGQMVHEQIVTYQSLPTLQISSPISLHQLQAVLGDLQWVSRGTPTTRRPLQLLYSSLKGIDDPRAIIQLSPEQLQGIAELRQALSHNARSRYN
LS2 ....................................................................................................




K02120   ..................................................................................................
AF257515 .......................................................................................L............
301 350 400
LS1   EQEPLLAYVHLTRAGSTLVLFQKGAQFPLAYFQTPLTDNQASPWGLLLLLGCQYLQTQALSSYAKPILKYYHNLPKASLDNWIQSSEDPRVQELLQLWPQ
LS2     ....................................................................................................




K02120   ............................................................................T.......................
AF257515 ..........................................................................V.TF.......C..............
401 450 500
LS1   ISSQGIQPPGPWKTLITRAEVFLTPQFSPDPIPAALCLFSDGATGRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLAGLAAAPPEPVNIWVDSKYLYSL
LS2     ....................................................................................................




K02120   ....................................................................................................
AF257515 ....V........................E.........................................................L............
501 550 endonuclease 600
LS1   LRTLVLGAWLQPDPVPSYALLYKSLLRHPAIFVGHVRSHSSASHPIASLNNYVDQLLPLETPEQWHKLTHCNPRALSRWPNPRISAWDPRSPATLCETCQ
LS2  ....................................................................................................




K02120   ...............................V........................................S...........................
AF257515 ......V.................................................................S..........V................
601 650 700
LS1   KLNPTGGGKMRTIQRGWAPNHIWQADITHYKYKQFTYALHVFVDTYSGATHASAKRGLTTQMTIEGLLEAIVHLGRPKKLNTDQGANYTSKTFVRFCQQF
LS2     ....................................................................................................




K02120   .............................................................T......................................
AF257515 ..........................................................................................R..A......
701 750 800
LS1   GVSLSHHVPYNPTSSGLVERTNGLLKLLLSKYHLDEPHLPMTQALSRALWTHNQINLLPILKTRWELHHSPPLAVISEGGETPKGSDKLFLYKLPGQNNR
LS2     ....................................................................................................




K02120   .................D..........................................................................L.......
AF257515 .......I............................................................................................
801 850
LS1        RWLGPLPALVEASGGALLATDPPVWVPWRLLKAFKCLKNDGPEDAHNRSSDG
LS2        ....................................................
LS2        ....................................................
EF600696   ....................................................
AF033818   ....................N...............P...............
FJ914764   .........I..........................P...............
K02120     ....................................................
AF257515   .........I..........................P...............
Figure 3 Alignment of amino acid sequences of Polymerase (Pol) proteins of BLV isolates. The reverse transcriptase (RT) region is shown in
green and the endonuclease region is shown in light blue. The rest is the same as Figure 1.
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| conformational epitopes F,G,H
1 Leader peptide | gp51 50 ND 100
LS1        MPKERRSRRRPQPIIRWVSLTLTLLALCRPIQTWRCSLSLGNQQWMTAYNQEAKFSISIDQILEAHNQSPFCAKSPRYTLDSVNGYPKIYWPPPQGRRRF
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ...K................................................................................................
AF033818   ............................Q..................T........................PR.......F..................
FJ914764   ............................Q.T..................................................F..................
K02120     ....................................................................................................
AF257515   ............................Q........F...........................................F..................
Conformational epitopes F,G,H |
101 ND 150CD8+-T Cell epitope   epitope E 200
LS1        GARAMVTYDCEPRCPYVGADRFDCPHWDNASQANQGSFYVNHQILFLHLKQCHGIFTLTWEIWGYDPLITFSLHKIPDPPQPDFPQLNSDWVPSVRSWAL
LS2        ....................H........................S......................................................
LS3        ....................H........................S......................................................
EF600696   .................................D..................................................................
AF033818   ....................H............D..................................................................
FJ914764   .................................D......D...................G.......................................
K02120     .................................D..................................................................
AF257515   .................................D......D...........................................................
201 epitope B epitope B’ 250 epitopes D D’ TMHR epitope A 300
LS1        LLNQTARAFPDCAICWEPSPPWAPEILVYNKTISSSGPGLALPDAQIFWVNTSSFNTTQGWHHPSQRLLFNVSQGNALLLPPISLVNLSTASSAPPTRVR
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   ..................................G..................L....................................V.........
FJ914764   .....................................................L...............I.............................K
K02120     ...................................................S................................................
AF257515   .....................................................L..A............I........V....F.G....GFF..S...K
301
| gp30 Fusion peptide 350 GD21 400
LS1        RSPVAALTLGLALSVGLTGINVAVSALSHQRLTSLIHVLEQDQQRLITAINQTHYNLLNVASVVAQNRRGLDWLYIRLGFQSLCPTINEPCCFLRIQNDS
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   ....................................................................................................
FJ914764   ....................................................................................................
K02120     ....................................................................................................
AF257515   ....................................................................................S...............
401 LHR TM Membrane span450 | cytoplasmic domain 500
LS1        IIRLGDLQPLSQRVSTDWQWPWNWDLGLTAWVRETIHSVLSLFLLALFLLFLAPCLIKCLTSRLLKLLRQAPHFPEISLTPKPDSDYQALLPSAPEIYSH
LS2        ....................................................................................................
LS3       ....................................................................................................
EF600696   ....................................................................................................
AF033818   ..............................................................................FP....................
FJ914764   ................................G....................................ES.......FA...................R
K02120     ..LR................................................................................................
AF257515   ................................G....................................ES........A...................R
501
LS1        LSPVKPDYINLRPCP
LS2        ...............
LS3        ...............
EF600696   ...............
AF033818   ...T...........
FJ914764   ...T...........
K02120     ...............
AF257515   ...T...........
Figure 4 Alignment of amino acid sequences of Envelope (Env) proteins of BLV isolates. Amino acid residues corresponding to gp51 (SU)
and gp30 (TM) proteins are shown on the top of the alignment. Leader peptide of SU is shown in green. Structural strong turn motif GYPD is
shown in bold, italics and double underlined. Conformational epitope region is indicated on top of the alignment. Linear epitopes are shown in
italics and underlined [41,42]. Receptor-binding domain (RBD) [43] residues are delimited by two triangles. Second strong turn, SSSG, is shown in
bold and italics. Amino acids involved in neutralization domains are shown in yellow. CD8 + −T epitope is shown in red. SU transmembrane
hydrophobic region (TMHR) is shown in light blue. TM fusion peptide is shown in light grey and residues believed to span host cell membranes
are indicated double lined. BLV leash and α-helical region (LHR) [35] is shown in bold, italics and underlined. Epitope GD21 is shown in magenta.
TM membrane-spanning region is shown in bold and italics. The cytoplasmic domain is indicated on top of the alignment. The rest is the same
as in Figure 1.




LS1   MASVVGWGPHSLHACPALVLSNDVTIDAWCPLCGPHERLQFERIDTTLTCETHRINWTADGRPCGLNGTLFPRLHVSETRPQGPRRLWINCPLPAVRAQP
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   .......................................................T.......F....................................
FJ914764   ...............................................P.......T.......F....A...............................
K02120     ....................................................................................................
AF257515   ...............................................H.......T.......F....A........RDPAPRA................
157  Leucine-rich activation domain 
LS1   GPVSLSPFERSPFQPYQCQLPSASSDGCPIIGHGLLPWNNLVTHPVLGKVLILNHMANFSLLPSFDTLLVDPLRLSVFAPDTRGAIRYLSTLLTLCPATC
LS2        ......................................................Q.............................................
LS2        ......................................................Q.............................................
EF600696   ...............................................R......Q.............................................
AF033818   .........Q............................................Q........P.................................V..
FJ914764 .............................V........................Q........P....................................
K02120     ......................................................Q.............................................
AF257515   .............................V........................Q........P.N..................................
261
240 247 251    258| 265                 287 297
LS1   ILPLGEPFSPNVPICRFPRDSNEPPLSEFELPLIQTPGLSWSVPAIDLFLTGPPSPCDRLHVWSSPQALQRFLHDPTLTWSELVASRKIRLDSPLKLQLL
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ....................................................................................................
AF033818   ....................TS..................................Y.............................G.L...........
FJ914764   ........................................................................................L...........
K02120     ................................P...................................................................
AF257515   ........................................................................................L...........
303
LS1   ENEWLSRLF
LS2        .........
LS3        .........
EF600696   .........
AF033818   .........
FJ914764   .........
K02120     .........
AF257515   .........
(B) Rex
NES
LS1   MPKERRSRRRPQPIIRWRQNYFLSFKQVLLVGGPTLYMPARPWFCPMMSPSMPGAPSAGPMSDSNSKGSTPRSPARPTVSTGPPMDDLAASMERCSLDCM
LS2        ....................................................................................................
LS3        ....................................................................................................
EF600696   ...K................................................................................................
AF033818   .............................................................N..................P.......L....H......
FJ914764   ...............................................T........................P.......P.......S...........
K02120     ....................................................................................................
AF257515   ...............................................T........................T.......P.......S...........
NLS
LS1   SPRPAPKGPDDSGSTAPFRPFALSPARFHFPPSSGPPSSPTNANCPRPLATVAPLSGTAFFPGTT
LS2        .................................................................
LS3        .................................................................
EF600696   .................................................................
AF033818   ..................................S...................S..........
FJ914764 ......................................................S..........
K02120     .................................................................
AF257515   ....G.................................................S..........
Figure 5 Alignment of amino acid sequences of Tax and Rex proteins of BLV isolates. In (A) the alignment of Tax sequences is shown. The
region between amino acids 240 and 265, in which missense mutations influence the transactivation activity of the Tax protein [46] is shown in
light blue. A putative zinc finger domain is shown in grey, a leucine-rich activation domain in yellow and sites of phosphorylation are indicated in
red. Position 303, where a previously described substitution E303K gave rise to a replication-deficient virus [47] is shown in green. Positions where
substitutions have been previously reported to have an effect on transactivation activity are shown in bold. In (B) alignment of Rex sequences is
shown. Nuclear export signal (NES) is shown in yellow and the nuclear localization signal (NLS) is shown in green. The rest is the same as
Figure 1.
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http://www.veterinaryresearch.org/content/44/1/19(amino acids 30 to 53), a transactivating domain (amino
acids 157 to 197) and two phosphorylation sites (amino
acids 106 and 293) [44] (see Figure 5A). A series of BLV
Tax mutants with strikingly more ability to stimulate
BLV LTR-directed transcription in comparison with
wild-type Tax have been previously described. All these
mutants have substitutions between amino acid 240 and
265 [45]. Amino acid changes previously related to
higher transcriptional activity as well as changes in the
previously described phosphorylation sites were not
observed in all the BLV isolates examined in the
present study (see Figure 5A). Only one substitution
was found in strain LS1 outside the leucine-rich acti-
vation domain (Figure 5A). Whether this amino acid
substitution has an effect on BLV transcription is cur-
rently unknown.
Previous studies revealed that silencing is critical for
tumor progression and distinct genetic and epigenetic
mechanisms were identified for complete suppression of
BLV Tax expression.
Conservation of sites involved in suppression of viral
expression may be an important factor for the uncon-
trolled proliferation of BLV-infected tumor cells [5].
The Rex proteins of Deltaretroviruses act to facilitate
the export of intron-containing viral RNA [48]. The Rex
proteins shuttle between nucleus and cytoplasm using
the nuclear localization signal (NLS) and nuclear export
signal (NES) (see Figure 5B). No significant substitutions
were found in Rex proteins of all BLV strains enrolled in
this study.
G4 protein amino acid sequence includes an amino-
terminal stretch of hydrophobic residues (amino acids 1
to 24) followed by potential proteolytic cleavage sites(A) G4
1  Leader peptide MYB
LS1    LACTRVCFLSYFLFLAARALSFGAQPHPVAFGPPFLTVPIKSLPFPQ
LS2    ...............................................








LS1         MPKERRSRRRPQPIIRWVLMNVFPCNKPQQRHSSHIQ*------
LS2         .....................................QHLGRLF
LS3         ............................*---------------
EF600696    ...K........................................
AF033818    .....................I......................
FJ914764    .....................I.............V........
K02120      ............................................
AF257515    .....................I.............V.......L
Figure 6 Alignment of amino acid sequences of accessory proteins R3
The leader peptide is shown in green, and the two putative cellular protea
alignment. The myb-like motif (MYB) and the arginine-rich nucleus targetin
sequences are shown. Termination codons are shown by an asterisk and inand an arginine-rich region (amino acids 58 to 72) lo-
cated in the middle of the protein [13] (see Figure 6A).
This latter region is required for the interaction of G4
with cellular protein farnesyl pyrophosphate synthetase
(FPPS), (phosphorylation) [49]. The biological relevance
of G4-FPPS interaction has been previously demonstrated
in cellular transformation. Mutations in the arginine-rich
α-helix of G4 abrogate primary cell immortalization and
induction of tumors in nude mice [49]. Therefore, disrup-
tion of the interaction between G4 and FPPS could inter-
fere with the oncogenic process.
No amino acid substitutions were found in the arginine-
rich α-helix of G4 protein of the previously sequenced BLV
isolates examined in this work (see Figure 6A). Neverthe-
less, an amino acid substitution (A29V) can be observed in
G4 of all BLV LSI.
Interestingly, premature stop codons were observed in
R3 of two of the three LS BLV isolates (Figure 6B). Pre-
vious studies on BLV infection using sheep provide
insight on the molecular genetic and epigenetic modula-
tion of viral expression [50]. These studies show that the
deletion of the region that expands from the end of the
env gene to the splice acceptor site of the tax/rex mRNA
does not impair infectivity [21]. These sequences corres-
pond to the third and second exons of R3 and G4, re-
spectively, revealing that these sequences may not be
essential for infectivity in vivo. Although previous stud-
ies have shown that deletions in R3/G4 interferes with
the efficiency of BLV propagation and restricts patho-
genesis [14,15,46,49], another study has shown that one
out of 20 sheep infected with a R3/G4 mutant developed
a lymphoma after 7.5 years of latency, suggesting that









and G4 of BLV isolates. In (A) alignment of G4 sequences is shown.
se cleavage sites are indicated by inverted triangles on top of the
g RNA-binding region (ARR) are shown in red. In (B) alignment of R3
dicated by an arrow.
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dress the biological significance of these findings in stud-
ies using the cow as a model for BLV infection.
In summary, although the genome of BLV is highly
conserved in our isolates and in isolates from other
sources previously described, variations can be observed
in some genome regions. It is thought that silencing of
viral expression is a multi-step process leading to the
uncontrolled growth of a transformed B-cell clone and
the onset of disease [5] and is critical for tumor progres-
sion and proliferation of BLV-infected tumor cells [5], as
well as escaping recognition by the host immune re-
sponse [4]. In that sense, the substitution found in the
GRE site of the 5′LTR of all BLV strains isolated from
the lymphosarcomas might contribute to these factors,
since previous studies have shown that substitutions in
GRE site significantly reduces basal LTR transcription
activity [52] (see Figure 1). Moreover, all amino acid sub-
stitutions in Tax previously found to be related to stimu-
late high transcriptional activity of 5′LTR were not
found in this study (see Figure 5A). Genetic and epigen-
etic mechanisms have been recently proposed for BLV
suppression of viral gene expression [53]. The results of
the present report, using full-length genome sequences,
suggest that point mutations along the whole genome
may also be needed to allow BLV provirus to achieve
silencing.
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